Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3923]

How can clinical trial units and networks help deliver high quality cancer...

Prof Usha Menon - University College London, London, UK

How can clinical trial units and networks help deliver high quality cancer trials ( Prof Usha Menon - University College London, London, UK )

Are remissions for AML patients 'better' after daunorubicin and cytarabine...

Prof Daniel Ryan - University of Rochester, Rochester, USA

Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection ( Prof Daniel Ryan - University of Rochester, Rochester, USA )

Is enasidenib plus azacitidine better than with azacitidine alone for AML...

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells...

Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern...

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )

Prognostic impact of chromosomal abnormalities and copy number alterations in B...

Prof Anthony Moorman - Newcastle University, Newcastle, UK

Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14 ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )

Long-term outcomes of subjects with EBV driven PTLD following solid organ or...

Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel ( Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA )

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT...

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )

Outcomes in patients with therapy-Related AML who achieved remission with CPX...

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa...

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )

Selective oestrogen receptor degraders as treatment for ER positive/HER2...

Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer ( Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium )

The challenges of treating breast cancer in Brazil

Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil

The challenges of treating breast cancer in Brazil ( Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil )

The importance of central pathology pCR review in an international multicenter...

Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany

The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC ( Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany )

SABCS 2019 highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

SABCS 2019 highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

More from ecancer